Technological progress can be a two-edged sword. On one hand, productivity improvements have reduced taxing physical labor, increased household wealth and afforded us more leisure time. On the other hand, as we have become more sedentary, agricultural advances have made food plentiful, contributing to an epidemic of obesity.
According to the Centers for Disease Control and Prevention, just 11% of American adults were obese (BMI over 30) in 1962. Today the number is 42%, and over 70% are either obese or overweight, driving billions of dollars in health care expenses each year. More alarmingly, the New England Journal of Medicine projects 60% of today’s children will be obese by the age of 35.
On yet another hand, scientific advances have brought us closer than ever to a magic bullet for weight loss: a new class of injectable drugs originally developed to treat type II diabetes that are remarkably effective. On the fourth hand, these miracle drugs are incredibly expensive, presenting a formidable obstacle to widespread adoption by those who would benefit the most and posing challenges to insurance companies and Medicare. No wonder Harry Truman yearned for a one-handed economist.
Most Americans are aware of the buzz surrounding these new weight loss medications. Approved in 2017 as a powerful treatment for diabetes, Novo Nordisk’s Ozempic proved to have salutary effects in shedding excess body fat and was approved for weight loss under the name Wegovy in 2021, yielding an average 12% loss of body weight compared with placebo. The active ingredient, semaglutide, replicates a natural hormone that induces insulin secretion that lowers blood glucose levels, slows emptying of the stomach and inhibits appetite. Last month, U.S. drugmaker Eli Lilly’s diabetes medication Mounjaro (tirzepatide) was approved for weight loss under the name Zepbound and proved even more effective, producing an average loss of 18% of body weight versus placebo.
Heightening the excitement, the 2023 AHA Scientific Sessions concluded with a bang upon the release of clinical trial data showing a 20% reduction in heart attack, stroke and cardiovascular death in patients taking semaglutide. The exact mechanism for the startling result is yet unknown, but the data got everyone’s attention.